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The tumour microenvironment consists of malignant cells, stroma, and immune cells. The role of adaptive immunity in
inducing a pathological complete response (pCR) in breast cancer with neoadjuvant chemotherapy (NAC) is well studied.
The contribution of innate immunity, however, is poorly documented. Breast tumours and axillary lymph nodes (ALNs)
from 33 women with large and locally advanced breast cancers (LLABCs) undergoing NAC were immunohistochemically
assessed for tumour-inﬁltrating macrophages (TIMs: M1 and M2), neutrophils (TINs), and dendritic cells (TIDCs) using
labelled antibodies and semiquantitative methods. Patients’ blood neutrophils (n = 108), DCs (mDC1 and pDC), and their
costimulatory molecules (n = 30) were also studied. Pathological results were classiﬁed as pCR, good (GPR) or poor (PRR).
In breast and metastatic ALNs, high levels of CD163+ TIMs were signiﬁcantly associated with a pCR. In blood, high levels
of neutrophils were signiﬁcantly associated with pCR in metastatic ALNs, whilst the % of mDC1 and pDC and expression
of HLA-DR, mDC1 CD40, and CD83 were signiﬁcantly reduced. NAC signiﬁcantly reduced tumour DCs but increased
blood DCs. PPRs to NAC had signiﬁcantly reduced HLA-DR, CD40, and CD86 expression. Our study demonstrated novel
ﬁndings documenting the diﬀerential but important contributions of innate immunity to pCRs in patients with LLABCs
undergoing NAC.
1. Background
Anticancer immune mechanisms play an important role in
the induction, development, and dissemination of malignant
disease in man [1–4]. Both innate and adaptive immune cells
have been documented in various human cancers (breast,
gastrointestinal, urogenital, head and neck, and melanoma),
and the presence of a prominent lymphocytic inﬁltrate is
associated with a good clinical outcome [4–8]. In women
with breast cancer undergoing neoadjuvant chemotherapy
(NAC), the presence of a high level of tumour-inﬁltrating
lymphocytes (TILs) has been shown to be an independent
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predictor of a complete pathological response (pCR) in the
breast tumour [9–13]. The presence of TILs inﬁltrating axil-
lary lymph node (ALN) metastases and their association with
a pCR, however, is less well studied (Kaewkangsadan et al.,
2016b submitted for publication).
The role of adaptive immunity (T eﬀector and regula-
tory cells, T helper (Th), and suppressor cytokines) in
women with breast cancer undergoing NAC has been
investigated in primary breast tumours, but much less so
in tumour-draining ALNs. Signiﬁcant associations have
been documented between high levels of inﬁltration by T
eﬀector cells (CD4+ and CD8+) and low levels of T
regulatory cells (Tregs: FOXP3+ (forkhead box protein 3)
and CTLA-4+ (cytotoxic T lymphocyte antigen-4)) and
subsequent pCRs with NAC in primary breast tumours
and ALN metastases [13–17]; (Kaewkangsadan et al.,
2016b submitted for publication). The contribution from
innate immunity (natural killer (NK) cells, macrophages,
neutrophils, and dendritic cells (DCs)) to breast cancer cell
death during NAC, however, is less well studied and
poorly documented.
We have recently described the key role played by NK
cells within primary breast tumours and tumour-draining
ALNs. Our studies have shown a signiﬁcant association
between high levels of tumour-inﬁltrating CD56+ NK cells,
in both the primary tumours and ALN metastases, and
subsequent pCRs with NAC. These ﬁndings highlight the
important contribution of innate immunity to immune-
mediated tumour cell death in patients with breast cancer
undergoing NAC.
Macrophages are terminally diﬀerentiated myeloid
cells, closely related to DCs, and are resident in tissues.
Human solid tumours recruit macrophages into their
microenvironment. Breast cancers, in particular, contain
a substantial number of macrophages [18]. Clinical and
experimental evidence indicate that tumour-inﬁltrating
macrophages (TIMs) play a major role in the initiation,
progression, and dissemination of malignant disease [19].
Two main polarised phenotypes (M1 and M2) have been
described. High levels of TIMs in most cancers, including
breast cancer, are associated with a poor disease-free
survival (DFS) and overall survival (OS) [20–23]. Heys et al.
described high levels of the M1 CD68+ TIMs in breast
cancers. [24]. Therefore, the association between M2
CD163+ TIMs and tumour response to NAC in both the
breast and ALNs was examined.
Polymorphonuclear leukocytes (neutrophils) play a
crucial role in dealing with invading pathogens and assist
in wound healing. They release a range of toxic substances
(reactive oxygen species and proteinases) to deal with
invading microorganisms [25]. Increased levels of circulat-
ing neutrophils have been documented in patients with
various solid cancers (breast, colon, pancreas, head and
neck, and melanoma) in the absence of overt infection
and inﬂammation. They have been shown to be immature,
producing low levels of free radicals and showing impaired
intracellular killing of pathogens [26]. Increased levels in
blood in various solid cancers have been shown to be
associated with poor clinical outcome [26]. Neutrophils
are recruited into the tumour milieu by chemotactic stim-
uli from macrophages and tumour cells and have been
described modifying tumour growth and invasiveness
[27–29]. The presence of CD66b+ tumour-inﬁltrating
neutrophils (TINs) has been shown to be associated with
a reduced DFS and OS in human cancers (renal, head
and neck, hepatic, and melanoma) [30–33]. There is a
dearth of data on the signiﬁcance of TINs in LLABCs
and the interaction with NAC and possible tumour pCR.
In this study, we have investigated the association between
TINs and subsequent pCR with NAC in both the primary
tumour and ALN metastases, and concurrently, neutrophils
in the circulation.
Dendritic cells (DCs) are derived from haematopoietic
progenitor cells in the bone marrow, monocytes being major
precursor cells. They are crucial antigen-presenting cells,
initiating and directing adaptive immune responses [34].
Various types have been categorised according to their
morphological characteristics, phenotypic proﬁles, and in
situ residence. Two main types, the large myeloid-derived
DC (mDC) and the small plasmacytoid DC (pDC), upregu-
late the expression of coregulatory and costimulatory mole-
cules (HLA-DR, CD40, CD80, and CD86) and the lymph
node homing (LNH) molecules (CD197), enhancing adap-
tive immunity [35–37].
Various factors, including tumour stroma-released che-
mokines and cytokines (CCL19 and transforming growth
factor-β (TGF-β)), hypoxia, and prostaglandins (PGE2),
act as chemoattractants and induce DC recruitment into
the tumour microenvironment [38]. DCs have been shown
to inﬁltrate various types of human tumours [39]. In
breast cancer, there is evidence that DCs in the tumour
microenvironment are present in very low numbers and
are poorly activated [40–42]. Moreover, dysfunctional
DCs (suppressive and tolerogenic) have been identiﬁed in
the circulation and tumour-draining ALNs in patients with
operable breast cancer [38, 43]. Coventry et al. demon-
strated a nonsigniﬁcant-enhanced 5-year survival rate in
patients with breast cancer whose tumours had high levels
of inﬁltration by CD1a+ DCs [44]. There is no published
data on the signiﬁcance and eﬀect of circulating and
TIDCs on pCR with NAC in breast cancer. We have
investigated this in the blood, breast, and ALNs in the
current study.
We have recently documented, in women with LLABCs
undergoing NAC, that a signiﬁcant reduction of both circu-
lating and tumour-inﬁltrating Tregs (FOXP3+, CTLA-4+)
and high levels of TILs and CD8+ T cells in the primary
and ALN metastatic tumours were signiﬁcantly associated
with subsequent pCRs [13]; (Kaewkangsadan et al., 2016b
submitted for publication). We also demonstrated that high
CD8+ : FOXP3+ T cell ratios in the primary breast tumours
and metastatic ALNs (tumour-free paracortex) were signiﬁ-
cantly associated with pCRs, highlighting the close and
complex interrelationships between NAC and adaptive
immunity. Furthermore, we recently described the important
relationship between NK cells (blood, tumour, and ALNs), a
key component of innate immunity, and NAC and pCR
responses [45]. We have studied further the role of other
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components (TIMs, neutrophils, and DCs (blood and
tumour)) of innate immunity in women with LLABCs
undergoing NAC and their possible contribution to the pCRs
that occur with chemotherapy and document our novel ﬁnd-
ings in this article.
2. Materials and Methods
2.1. Patients and Samples. Paraﬃn-embedded sections of
breast tumours and tumour-draining ALNs from 33 women
with large (L: ≥3 cm) and locally advanced breast cancers
(LABCs: T3, 4; N1, 2; M0), enrolled in a study of NAC (108
patients enrolled between 2008 and 2011), were studied [46].
Histological diagnosis was established from ultrasound-
guided core biopsies. To minimise tumour heterogeneity
and sampling discrepancies, several core biopsies were
obtained from each tumour. All tumours prior to NAC had
a radiopaque coil inserted. Post-NAC, wire-guided removal
of the residual “tumour” was carried out (in the case of breast
conservation) if there was no clinical or radiological evidence
of cancer. Operative specimens (wide local excision and mas-
tectomy) had radiological conﬁrmation of the presence of the
coil to ensure accurate localisation and histopathological
evaluation. Twenty-four patients had nodal metastases, and
9 patients were without nodal metastases; 20 out of 24
patients with nodal metastases had additional pre-NAC
ultrasound-guided core needle biopsy samples of metastatic
tumours in ALNs. Representative tissue sections were used
for immunohistochemical (IHC) evaluation. All pre- and
post-NAC specimens were discussed at a multidisciplinary
meeting and a consensus reached about the pathological
response and treatment options.
The NAC trial evaluated the eﬀect of the addition of
capecitabine (X) to docetaxel (T) preceded by adriamycin
and cyclophosphamide (AC). Pathological responses were
assessed in the excised surgical specimens after NAC. Estab-
lished and previously published grading criteria were used to
deﬁne histopathological responses in the breast [47, 48].
Good pathological responses were graded 5 (pCR, no residual
invasive disease) and 4 (≥90% loss of invasive disease).
Patients with grade 5 and 4 responses constituted the good
pathological responders (GPRs). Poor pathological responses
were graded as 3 (30–90% loss of invasive disease), 2 (<30%
loss of invasive disease), and 1 (no loss of tumour cells).
Patients with these responses constituted the PPR group.
Pathological responses in metastatic tumours in ALNs were
deﬁned as pCR (grade 3: complete disappearance of tumour
deposits or replacement by ﬁbrosis in a previously histo-
logically conﬁrmed metastatic ALN); pathological partial
response (grade 2: residual metastatic tumour deposits pres-
ent with evidence of tumour destruction and replacement by
ﬁbrosis); and no pathological response (grade 1: metastatic
tumour deposits remain with no evidence of ﬁbrosis). Patient
cases were randomly selected based on availability of tissue
specimens and to ensure an even distribution between com-
pared groups (pCR versus non-pCR).
The study was given approval by the Leicestershire,
Northamptonshire & Rutland Research Ethics Committee
1: Reference number 07/H0406/260; Favourable Opinion
24/01/2008. All patients enrolled in the study gave informed
consent to participate in and to publish the results of the
study. The study registration is ISRCTN00407556.
2.2. Blood DC Phenotyping. Venous blood samples were
collected before (n = 30) and following completion of NAC
(n = 16). These blood samples were from the same patients
whose tumour and nodal specimens were investigated
immunohistochemically for CD1a+ DCs. Venous blood sam-
ples were also collected from 10 age-and sex-matched healthy
female donors (HFDs) to establish normal values. Peripheral
blood mononuclear cells (PBMCs) were isolated by centrifu-
gation on Ficoll-Hypaque, washed and made up in RPMI
with 10% foetal calf serum (FCS) (Sigma, UK) and antibiotics
(TCM), and stored at −80°C for further analysis.
The mDC1high (Lin1−, HLA-DR+, CD11c+, and CD1c+)
and the pDChigh (Lin1−, HLA-DR+, CD11c+, and CD303+)
subsets and their costimulatory molecules were documented
in 2× 106 cells/100 μl of PBMCs and stained for cell surface
markers for 30 minutes (mins) with 5 μl ﬂuorescein isothio-
cyanate (FITC) anti-human LIN1, 5 μl Texas red conjugate
(ECD) anti-human HLA-DR, 5 μl Paciﬁc Blue anti-human
CD11c, 5 μl allophycocyanin (APC) Cy7 anti-human
CD40, 5 μl Pe-Cy7 anti-human CD80, 5 μl APC anti-
human CD86, 5 μl Alexa 700 anti-human CD197, 2.5 μl
Percp-ﬂuor-710 anti-human CD1c (BDCA-1) for mDCshigh,
and 5 μl CD303-PE (BDCA-2) for pDCshigh which were
added to the corresponding tubes and incubated for 30mins
at 4°C. The PBMC pellet was washed twice in phosphate-
buﬀered saline. The PBMCs were then resuspended in 400
μl of 0.5% paraformaldehyde ﬁxative solution for ﬂow cyto-
metric analysis on a Beckman Coulter FC500.
Blood neutrophil counts (pre- and post-NAC) in 108
women with LLABC were collected and used in the analysis
to evaluate association with NAC-induced pCR in the breast
and tumour-draining ALNs.
2.3. Immunohistochemical (IHC) Assessment. Immunohisto-
chemical assessments of immune cell subsets and expression
of indoleamine 2,3-dioxygenase (IDO) and vascular endo-
thelial growth factor (VEGF) were performed in 4 μm tissue
sections. Brieﬂy, paraﬃn-embedded tissue sections were
dewaxed and rehydrated using xylene and graded alcohol.
Citrate buﬀer, pH 6.0, at 98°C was added for 20mins for anti-
gen retrieval. After serial blocking, the sections were incu-
bated with the primary monoclonal antibody (MAb)
against CD68 (Abcam, ab955, clone KP1), 1 : 300 dilution
for 30mins at room temperature (RT); MAb against CD163
(Abcam, ab74604, clone 10D6), prediluted for 30mins at
RT; MAb against CD1a (Dako, M3571, clone 010), 1 : 200
dilution for 15mins at RT; MAb against CD66b (LS Bio,
LS-B7134, clone 80H3), 10 μg/ml for 30mins at RT; MAb
against IDO (Abcam, ab55305), 0.75 μg/ml for 15mins at
RT; and MAb against VEGF (Dako, M7273, clone VG1),
1 : 50 dilution for 30mins at RT. The Novolink™ polymer
detection system, Leica RE7280-K with polymeric horserad-
ish peroxidase- (HRP-) linker antibody conjugates and
diaminobenzidine (DAB) chromogen, was used for enzyme-
substrate labelling. Finally, the sections were counterstained
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with haematoxylin, dehydrated, and mounted in DPX
mounting medium. Positive and negative staining controls
were carried out with tonsil sections except for CD163 (liver
sections) and IDO (normal colon sections). Negative staining
controls were demonstrated by omitting the primary anti-
body. Positive and negative controls were simultaneously
performed with every IHC staining run. All primary antibod-
ies used in this study have been validated and certiﬁed by the
commercial suppliers for IHC assessment of paraﬃn-
embedded specimens.
2.4. Semiquantiﬁcation of IHC Sections.Whole tissue sections
were studied rather than microarrays (to minimise sampling
bias). The majority of macrophages present in breast
tumours were located along the border of tumour nests.
Immunostaining for TIMs was evaluated along the tumour
front (TF) over the whole section (7–10 view ﬁelds per sec-
tion). This evaluation followed previously published studies
documenting the level of TIMs [49–51]. Tumour tissue con-
taining small areas of prominent inﬁltration of CD68+ or
CD163+ cells, which was considerably higher than the aver-
age level of CD68+/CD163+ cells, was deﬁned as hotspots
(TF hotspot). All sections were evaluated at a distance away
from areas of necrosis. The TF hotspots of the two view ﬁelds
with the highest measurements at ×200 magniﬁcation were
averaged out (CD68 or CD163 TF mean). The average inﬁl-
tration (CD68 or CD163 TF mean) was semiquantitatively
graded as no/weak (grade 1), moderate (grade 2), strong/
robust (grade 3), and massive inﬁltration (grade 4). Tumours
classiﬁed as 1 included totally negative specimens as well as
specimens containing some scattered positively stained cells
along the tumour margin. Tumours were classiﬁed as 2 when
CD68 or CD163 staining was continuous along the tumour
margin but did not extend from the tumour front for more
than one cell layer on average. CD68 or CD163 staining that,
on average, extended two to three cell layers from the tumour
margin over the whole section was classiﬁed as 3; CD68 or
CD163 staining extending more than three cell layers from
the tumour margin in all ﬁelds was classiﬁed as 4. For statis-
tical analysis, grades 1 and 2 were deﬁned as low level of inﬁl-
tration whereas grades 3 and 4 were deﬁned as high level of
inﬁltration [49–51].
To evaluate the presence and extent of CD1a+ and
CD66b+ cells in the breast tumours, the average numbers of
brown membrane-stained cells regardless of the intensity
were counted in 5 high-power ﬁelds (400x HPFs). Positively
stained cells in contact with tumour cells or within the
tumour cell nests were deﬁned as “intratumoural” whereas
positively stained cells in the interstitial stroma surrounding
tumour nests were deﬁned as “peritumoural/stromal.” Eval-
uation of inﬁltrations in post-NAC specimens was under-
taken on residual tumour nests, and in the case of pCR
(complete disappearance of invasive tumour cells in the
specimen), in the tumour bed. The latter was characterised
histologically as a hyalinised, amorphous area with haemosi-
derin deposits [52, 53].
Positively stained macrophages (CD68+ and CD163+) in
ALNs were quantiﬁed as the average % of all cells in 5 HPFs
in nonmetastatic medullary areas of ALNs. The average
number of cell counts in 5 HPFs in nonmetastatic areas with
the greatest accumulations of positively stained cells on
scanning at low magniﬁcation was determined for
CD66b+ and CD1a+ cells. These quantitative evaluations
followed the methodological scoring for documenting
various immune cell subsets present in ALNs in patients
with breast cancer [42, 54].
To evaluate the presence of IDO and VEGF, the semi-
quantitative H scoring system was employed using whole
tissue sections. The H score was calculated by multiplying
the % of positive cells (tumour and immune) by a factor
Table 1: Analyses of tumour-inﬁltrating CD68+ and CD163+ macrophages in the breast tumours in women with LLABCs and subsequent
PCR following NAC.
Macrophages Groups
Pre-NAC
Low inﬁltration (n) High inﬁltration (n)
Pearson chi-square value (GPR versus
PPR, PCR versus non-PCR)
p value
CD68+
(n = 16)
Good pathological response
(GPR, n = 9) 5 4
1.667 0.197
Poor pathological response
(PPR, n = 7) 6 1
Pathological complete response
(PCR, n = 6) 3 3
1.571 0.210
Nonpathological complete
response (non-PCR, n = 10) 8 2
CD163+
(n = 33)
Good pathological response
(GPR, n = 21) 5 16
8.192 0.004∗
Poor pathological response
(PPR, n = 12) 9 3
Pathological complete response
(PCR, n = 16) 3 13
7.127 0.008∗
Nonpathological complete
response (non-PCR, n = 17) 11 6
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; ∗statistically signiﬁcant.
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representing the intensity of immune reactivity (1 for weak, 2
for moderate, and 3 for strong), giving a maximum score of
300. A score of <50 was considered negative, and a score of
50–100 was considered weakly positive (1+). A score of
101–200 was regarded as moderately positive (2+) and a
score of 201–300 as strongly positive (3+). Negative and 1+
were considered as low expression whereas 2+ and 3+ were
considered as high expression [55, 56].
All scored assessments were performed without the
knowledge of the patients’ clinical and pathological parame-
ters. The pathological responses were assessed by a consultant
breast pathologist. The scoring systems used in establishing
the biological markers present in breast tumours and
metastatic tumours in ALNs, and ALNs in this investigation,
followed previously published studies documenting the scor-
ing systems employed (described above).
2.5. Statistical Analysis. Statistical analyses were performed
with the IBM SPSS statistics software, version 21 (SPSS Inc.,
Chicago, IL, USA). Where the data did not follow a normal
distribution, a nonparametric test (Mann–Whitney U test
(between two variables/groups)) was used to compare the
groups based on pathological responses. The Pearson chi-
square test was performed to compare the binomial data
(a) (b)
(c) (d)
Figure 1: CD68+ (a, b) and CD163+ (c, d) macrophages in the sections of LLABCs, using IHC staining, at 200x magniﬁcation. Brieﬂy, heat-
mediated antigen retrieval was performed using citrate buﬀer, pH 6 (20mins). The sections were then incubated withMAbs to CD68 (Abcam,
ab955) at a 1 : 300 dilution for 30mins at RT, MAbs to CD163 (Abcam, ab74604) at a prediluted concentration for 30mins at RT. Polymeric
HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. The sections were
counterstained with haematoxylin. (a, c) Low level of CD68+ and CD163+ macrophage inﬁltration; (b, d) high level of CD68+ and
CD163+macrophage inﬁltration. Tumours were classiﬁed as low level of inﬁltration when the positively brown membrane-stained cells
were scattered or continuous along the tumour margin but did not extend from the tumour front (TF) for more than one cell layer.
Extension for two or more layers from the TF was classiﬁed as a high level of inﬁltration.
Table 2: Alteration of tumour-inﬁltrating CD68+ and CD163+ macrophages in the breast tumours in women with LLABCs undergoing NAC.
Macrophages Groups
Post-NAC
p value(3) (pre- versus post-NAC)
Low inﬁltration (n) High inﬁltration (n)
CD68+ (n = 16) Pre-NAC Low inﬁltration (n) 10 1 0.375
High inﬁltration (n) 4 1
CD163+ (n = 16) Pre-NAC Low inﬁltration (n) 4 2 0.289
High inﬁltration (n) 6 4
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)related sample McNemar test.
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(negative/low versus high) on level of TIMs and expression of
IDO/VEGF between groups. To evaluate and compare the
related sample data between pre-NAC and post-NAC
groups, as well as primary breast tumours and metastatic
tumours in ALNs, the related sample Wilcoxon signed-rank
test and related sample McNemar test were performed for
comparing the number of cell counts and the expression of
IDO/VEGF, respectively. A probability value (p value) of
equal to or less than 0.05 (2 tailed) was considered statisti-
cally signiﬁcant.
The sample size of this study was based on a cohort of
patients from a previous study in which circulating Tregs
were documented pre- and post-NAC [57]. A sample size
of at least 7 in each group having an 80% power to detect a
diﬀerence between two groups with p values of ≤0.05 (two
sided) was calculated by assuming the common standard
deviation of circulating blood Tregs as 0.5. As our ﬁndings
are derived from several assays of diﬀerent parameters, the
sample size of at least 7 in each group may not be optimal
for some of the tests. In addition, multiple hypothesis testing
may lower the signiﬁcance of our ﬁndings.
3. Results
3.1. Patient and Tumour Characteristics and Responses to
NAC. The patient and tumour characteristics of the 33
Table 3: Analyses of CD163+ macrophages in metastatic tumours in ALNs in women with LLABCs and subsequent PCR following NAC.
Groups
Pre-NAC
Low inﬁltration (n) High inﬁltration (n)
Pearson chi-square value
(PCR versus non-PCR)
p value
CD163+
macrophages
(n = 20)
Pathological complete response
(PCR, n = 9) 0 9
8.811 0.003∗
Nonpathological complete response
(non-PCR, n = 11) 7 4
ALNs: axillary lymph nodes; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; ∗statistically signiﬁcant.
(a) (b)
(c) (d)
Figure 2: CD68+ (a, b) and CD163+ (c, d) macrophages in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magniﬁcation. Brieﬂy, heat-mediated antigen retrieval was performed using citrate buﬀer, pH 6 (20mins). The sections were then
incubated with MAbs to CD68 (Abcam, ab955) at a 1 : 300 dilution for 30mins at RT, MAbs to CD163 (Abcam, ab74604) at a prediluted
concentration for 30mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was
used to visualize the staining. The sections were counterstained with haematoxylin. (a, c) Low percentage of CD68+ and CD163+
macrophages; (b, d) high percentage of CD68+ and CD163+macrophages. The positive brown membrane-stained cells in tumour-free
medullary areas of ALNs were quantiﬁed as the average % of all cells (5 HPFs).
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patients studied are shown in Table A (Supplementary Table
available online at https://doi.org/10.1155/2017/1049023).
The responses to NAC and the tumour recurrence and
survival at 4 years of follow-up are documented.
3.2. High Levels of Inﬁltration of Breast Tumours in LLABCs
by CD68+ and CD163+ Macrophages and Subsequent PCR
with NAC. High levels of CD163+ TIMs in breast can-
cers were signiﬁcantly associated with a GPR and
pCR (p = 0 004, p = 0 008), respectively, following 8 cycles
of NAC. There was, however, no signiﬁcant association
between CD68+ TIMs and GPR and pCR with NAC
(Table 1). Figure 1 illustrates the presence of high and low
levels of inﬁltration by CD68+ (Figures 1(a) and 1(b)) and
CD163+ macrophages (Figures 1(c) and 1(d)) in the primary
tumours.
Eight cycles of NAC, on the other hand, did not alter the
level of inﬁltration by CD68+ and CD163+ TIMs in post-
NAC tumour specimens when compared with pre-NAC
specimens (Table 2).
3.3. High Levels of Inﬁltration of ALN Metastases in LLABCs
by CD163+ Macrophages and Subsequent PCR with NAC.
High levels of CD163+ TIMs in metastatic deposits in
tumour-draining ALNs were signiﬁcantly associated with a
pCR (p = 0 003). As the levels of CD68+ TIMs in primary
tumours showed no association with a pCR following NAC,
we elected not to study this subset in the ALN metastases
(Table 3). Figure 2 illustrates CD68+ (Figures 2(a) and 2(b))
and CD163+ macrophages (Figures 2(c) and 2(d)) in the
ALNs (tumour-free medullary areas).
Comparison of primary breast cancers with ALN
metastases showed no signiﬁcant diﬀerences in the levels of
inﬁltration by CD163+ TIMs (Table 4).
3.4. Tumour Inﬁltration of Breast Tumours in LLABCs by
CD1a+ DCs and CD66b+ Neutrophils Was Not Associated
with a PCR following NAC. Neither good pathological
responders nor those whose tumours had a pCR with NAC
had a signiﬁcant association with pre-NAC CD1a+ TIDCs
or CD66b+ TINs. The inﬁltration was assessed both
intratumourally and peritumourally (stroma) (Table 5).
Figures 3(a) and 3(b) illustrate CD1a+ TIDCs and
Figures 3(c) and 3(d) CD66b+ TINs in the tumour speci-
mens examined. There was, however, a signiﬁcant reduc-
tion in the level of intratumoural inﬁltration, but not
peritumoural, by CD1a+ TIDCs with NAC (p = 0 001).
Table 4: Comparison of CD163+ macrophages between primary breast tumours and ALN metastatic tumours in women with LLABCs.
Groups
Metastatic tumours in ALNs p value(3) (primary versus
metastases)Low inﬁltration (n) High inﬁltration (n)
CD163+
macrophages
Primary tumours in
breast
Low inﬁltration
(n)
6 2
1.000
High inﬁltration
(n)
1 11
ALN: axillary lymph node; LLABCs: large and locally advanced breast cancers; (3)related sample McNemar test.
Table 5: Analyses of tumour-inﬁltrating CD1a+ dendritic cells and CD66b+ neutrophils in the breast tumours in women with LLABCs and
subsequent PCR following NAC.
Cell
subsets
Groups
Pre-NAC
intratumoural
median (range)(3)
p value(3) (GPR versus
PRR, PCR versus
non-PCR)
Pre-NAC
peritumoural median
(range)(3)
p value(4) (GPR versus PRR,
PCR versus non-PCR)
CD1a+
(n = 16)
Good pathological response
(GPR, n = 9) 3 (1–104)
0.837
1 (1–16)
0.837
Poor pathological response
(PPR, n = 7) 11 (0–63) 2 (0–11)
Pathological complete
response (PCR, n = 6) 3 (1–104)
0.713
1.5 (1–16)
0.492
Nonpathological complete
response (non-PCR, n = 10) 4 (0–63) 1.5 (0–11)
CD66b+
(n = 16)
Good pathological response
(GPR, n = 9) 2 (0–53)
0.174
2 (0–71)
0.408
Poor pathological response
(PPR, n = 7) 1 (0–3) 1 (0–2)
Pathological complete
response (PCR, n = 6) 3 (0–53)
0.181
5 (0–71)
0.118
Nonpathological complete
response (non-PCR, n = 10) 1 (0–3) 1 (0–2)
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)total cell count per 5 high-power ﬁelds (core biopsies of breast
cancers); (4)Mann–Whitney U test.
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There was, on the other hand, no intra- or peritumoural
alteration in the level of CD66b+ TINs (Table 6).
3.5. No Signiﬁcant Diﬀerence in the Levels of Macrophages
(CD68+ and CD163+), Neutrophils, and DCs in ALNs
(Metastatic versus Nonmetastatic) in Women with LLABCs
Undergoing NAC. There was no signiﬁcant diﬀerence in the
level of macrophages (CD68+ and CD163+) in tumour-
draining ALNs, comparing metastatic (tumour-free areas)
with nonmetastatic, in women with LLABCs undergoing
NAC (Table 7). Similarly, there was no signiﬁcant diﬀerence
in the levels of CD1a+ DCs or CD66b+ neutrophils (Table 7).
The presence of CD66b+ neutrophils and CD1a+ DCs
in ALNs in tumour-free paracortical areas of ALNs is
illustrated in Figures 4(c) and 4(d) and Figures 4(a) and
4(b), respectively.
3.6. Expression of VEGF and IDO in Women with LLABCs
Undergoing NAC: CPR Signiﬁcantly Associated with High
Levels of VEGF in Pre-NAC Breast Cancers. High levels of
(a) (b)
(c) (d)
Figure 3: CD1a+ DCs (a, b) and CD66b+ neutrophils (c, d) in the sections of LLABCs, using IHC staining, at 400x magniﬁcation. Brieﬂy,
heat-mediated antigen retrieval was performed using citrate buﬀer, pH 6 (20mins). The sections were then incubated with MAbs to CD1a
(Dako, M3571) at a 1 : 200 dilution for 15mins at RT, MAbs to CD66b (LSBio, LS-B7134) at a concentration of 10 μg/ml for 30mins at
RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. The
sections were counterstained with haematoxylin. (a, c) Low level of CD1a+ DC and CD66b+ neutrophil inﬁltration; (b, d) high level of
CD1a+ DC and CD66b+ neutrophil inﬁltration. The total number of brown membrane-stained cells, regardless of intensity, in contact
with tumour cells or within tumour cell nests (Itu: intratumoural) and in the interstitial stroma (Str: stromal/peritumoural) in 5 HPFs was
counted.
Table 6: Alteration of tumour-inﬁltrating CD1a+ dendritic cells and CD66b+ neutrophils in breast tumours in women with LLABCs
undergoing NAC.
Groups Pre-NACmedian (range)(3) Post-NACmedian (range)(3) p value(4) (pre- versus post-NAC)
CD1a+
Intratumoural inﬁltration (n = 16) 3.5 (0–104) 0 (0–2) 0.001∗
Peritumoural inﬁltration (n = 16) 1.5 (0–16) 1 (0–7) 0.184
CD66b+
Intratumoural inﬁltration (n = 16) 1 (0–53) 4.5 (0–50) 0.125
Peritumoural inﬁltration (n = 16) 1.5 (0–71) 2.5 (0–82) 0.470
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)cell count in 400x HPF; (4)Wilcoxon signed-rank test; ∗statistically
signiﬁcant.
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expression of VEGF in primary breast cancers were signiﬁ-
cantly associated with a pCR (p = 0 018) following NAC.
There was no association, however, with the expression
of IDO (Table 8). In addition, there was no alteration of
IDO and VEGF in the primary breast cancers following
NAC (Table 9).
Figure 5 illustrates the expression of VEGF (Figures 5(a)
and 5(b)) and IDO (Figures 5(c) and 5(d)), respectively, in
primary breast cancers.
There was no diﬀerence in the expression of IDO and
VEGF in ALNs, whether metastatic (tumour-free paracorti-
cal area) or nonmetastatic (data not shown).
Table 7: Analyses of immune cell subsets in ALNs in women with LLABCs undergoing NAC.
Immune cell subsets Groups ALN median (range)(4) p value(5)
CD68+ macrophages (n = 16) Nonmetastatic ALNs (n = 9) 25.0 (14.8–34.0) 0.918
Metastatic ALNs (n = 7) 29.0 (13.8–33.0)
CD163+ macrophages (n = 33) Nonmetastatic ALNs (n = 9) 21.0 (16.0–29.0) 1.000
Metastatic ALNs (n = 24) 23.0 (10.0–33.0)
CD1a+ DCs (n = 16) Nonmetastatic ALNs (n = 9) 12.8 (0.8–62.0) 0.536
Metastatic ALNs (n = 7) 23.8 (6.6–67.0)
CD66b+ PMNs (n = 16) Nonmetastatic ALNs (n = 9) 5.2 (0.6–94.0) 0.837
Metastatic ALNs (n = 7) 8.4 (1.0–163.0)
ALNs: axillary lymph nodes; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (4)average percentage of positively stained
cells out of all the lymphoid cells in the ALN sections examined for CD68+ and CD163+ macrophages, average cell count of positively stained cells per 400x
high-power ﬁeld in the ALN sections examined for CD1a+ DCs and CD66b+ PMNs; (5)Mann–Whitney U test; DCs: dendritic cells; PMNs:
polymorphonuclear leukocytes.
(a) (b)
(c) (d)
Figure 4: CD1a+ DCs (a, b) and CD66b+ neutrophils (c, d) in the sections of axillary lymph nodes (ALNs), using IHC staining, at 400x
magniﬁcation. Brieﬂy, heat-mediated antigen retrieval was performed using citrate buﬀer, pH 6 (20mins). The sections were then
incubated with MAbs to CD1a (Dako, M3571) at a 1 : 200 dilution for 15mins at RT, MAbs to CD66b (LSBio, LS-B7134) at a
concentration of 10 μg/ml for 30mins at RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen
was used to visualize the staining. The sections were counterstained with haematoxylin. (a, c) Low number of CD1a+ DCs and CD66b+
neutrophils; (b, d) high number of CD1a+ DCs and CD66b+ neutrophils. The average number of cell counts per HPF in tumour-free
paracortical areas of ALNs with the greatest accumulation of the positive brown membrane-stained cells was quantiﬁed.
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Figure 6 illustrates the expression of VEGF (Figures 6(a)
and 6(b)) and IDO (Figures 6(c) and 6(d)), respectively, in
ALNs.
3.7. Signiﬁcant Association between ER Status and Tumour
Grade with CD163+ TIMs and PCR. High levels of
CD163+ TIMs were signiﬁcantly associated with ER sta-
tus (p = 0 046) and tumourgrade (p = 0 004). In addition, both
parameters were signiﬁcantly associated with tumour pCRs
following NAC (p = 0 049, p = 0 010, resp.) (Table 10). Thus,
ER-ve, high grade tumours were more likely to be inﬁltrated
by TIMs and show a pCR with NAC. There was also a
signiﬁcant inverse associationbetweenpCRand recurrent dis-
ease (4-year follow-up) in the small group of patients (n = 33)
studied (p = 0 001) (Table 10).
3.8. High Circulating Levels of PMN Neutrophils (Pre-NAC):
Signiﬁcant PCR inMetastatic ALNs.High levels of circulating
PMN neutrophils pre-NAC in women with LLABCs
(n = 108) were associated with a signiﬁcant pCR in metastatic
ALNs following 8 cycles of NAC. There were no comparable
changes in the primary breast cancers, nor any signiﬁcant
associations with nodal status, DFS and OS (Table 11).
There was also no signiﬁcant correlation between blood
Table 9: No alteration of expression of IDO and VEGF in the breast tumours in women with LLABCs undergoing NAC.
VEGF/IDO (n = 16) Groups Post-NAC p value(5)
Low/negative expression (n) High expression (n)
VEGF Pre-NAC
Low/negative expression (n) 8 3
1.000
High expression (n) 3 2
IDO Pre-NAC
Low/negative expression (n) 8 3
1.000
High expression (n) 2 3
IDO: indoleamine 2,3-dioxygenase; VEGF: vascular endothelial growth factor; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant
chemotherapy; (5)related sample McNemar Test.
(a) (b)
(c) (d)
Figure 5: VEGF (a, b) and IDO (c, d) expression in the sections of LLABCs, using IHC staining, at 400x magniﬁcation. Brieﬂy, heat-mediated
antigen retrieval was performed using citrate buﬀer, pH 6 (20mins). The sections were then incubated with MAbs to VEGF (Dako, M7273) at
a 1 : 50 dilution for 30mins at RT, MAbs to IDO (Abcam, ab55305) at a concentration of 0.75 μg/ml for 15mins at RT. Polymeric HRP-linker
antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. The sections were counterstained
with haematoxylin. (a, c) Low level of expression; (b, d) high level of expression. The H score (% of positive cells (brown membrane/
cytoplasmic-stained tumour and immune cells)× intensity of staining (1 to 3)) was used to assess the level of expression; low was ≤100
and high was >100. Scoring performed on a whole tissue section (7–10 HPFs); Tu: tumour, Ma: macrophage, and Ly: lymphocyte.
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and tumour-inﬁltrating CD66b+ neutrophils in patients
following 8 cycles of NAC (data not shown). There was
a signiﬁcant reduction in the circulating levels of PMN
neutrophils (p = 0 001) after NAC (Table 12). All patients
were given granulocyte colony-stimulating factor (G-CSF)
following randomisation.
3.9. Circulating Levels of DCs, mDC1s and pDCs, and
Expression of Costimulatory and Lymph Node Homing
Molecules in Women with LLABCs: Reduction in Blood
Levels and Expression of Costimulatory Molecules. The %
of DCs in the blood of women with LLABCs (n = 30)
was signiﬁcantly reduced (1.26± 0.20%) compared with
healthy, age-matched female donors (HFDs (n = 9): 1.70
± 0.30) (p = 0 034). The % of mDC1shigh was also signiﬁ-
cantly reduced compared with HFDs (0.10± 0.04% versus
0.15± 0.05%, p = 0 045), as was the % pDCshigh (0.03
± 0.02% versus 0.06± 0.02%, p = 0 041) (Table 13).
The expression of the costimulatory molecule HLA-
DR was signiﬁcantly reduced in both the blood mDC1+ and
pDC+ subsets, compared with HFDs (47.30± 8.00% versus
65.00± 3.10% (p = 0 045), 48.12± 9.50% versus 65.52
± 5.00% (p = 0 002), resp.) (Table 13).
The expression of CD40 and CD83 was also depressed in
mDC1shigh, compared with HFDs (35.01± 8.00% versus
44.87± 6.50% (p = 0 011), 3.18± 0.40% versus 4.04± 0.30%
(p = 0 047), resp.). The expression of CD80, CD86, and
LNHR CD197 on the mDC1shigh were unaltered (Table 13).
The levels of expression of these receptors on pDCs were
inconsistent and diﬃcult to document due to the small
numbers of these cells in the blood, and apart from HLA-
DR expression, are not shown.
3.10. Eﬀect of NAC on the Circulating Levels of DCs in
Women with LLABCs: Good Pathological Responders Have
Signiﬁcantly Increased Blood Levels following NAC. Before
NAC, the % baseline levels of DCs in women who subse-
quently had a good pathological response with NAC (n = 9)
were comparable with those that had a poor pathological
response (n = 7) (1.64± 0.25 versus 1.29± 0.25) (Table 14).
The % levels of blood DCs following 8 cycles of NAC
and in those who had a good pathological response
(pCR or ≥90% reduction in tumour mass) with NAC,
however, were increased. This was even signiﬁcantly
higher than the levels documented in HFDs (3.24± 1.62
versus 1.70± 0.30, p = 0 024) (Table 14). There was no
alteration in the post-NAC levels of circulating DCs in
those patients whose tumours showed a poor pathological
response (no response or <90% reduction in tumour mass)
(Table 14).
(a) (b)
(c) (d)
Figure 6: VEGF (a, b) and IDO (c, d) expression in the sections of axillary lymph nodes (ALNs), using IHC staining at 400x magniﬁcation.
Brieﬂy, heat-mediated antigen retrieval was performed using citrate buﬀer, pH 6 (20mins). The sections were then incubated with MAbs to
VEGF (Dako, M7273) at a 1 : 50 dilution for 30mins at RT, MAbs to IDO (Abcam, ab55305) at a concentration of 0.75 μg/ml for 15mins at
RT. Polymeric HRP-linker antibody conjugate was used as secondary antibody. DAB chromogen was used to visualize the staining. The
sections were counterstained with haematoxylin. (a, c) Low level of expression; (b, d) high level of expression. The H score (% of positive
cells (brown membrane/cytoplasmic-stained cells)× intensity of staining (1 to 3)) was used to assess the level of expression; low was ≤100
and high was >100. Scoring performed on nonmetastatic areas of a whole ALN section (7–10 HPFs).
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3.11. Eﬀect of NAC on the Circulating Levels and Expression of
Costimulatory Molecules on mDC1s and pDCs: Blood Levels
and Expression Lower in PPRs. After 8 cycles of NAC, those
women whose breast cancers showed a PPR had sig-
niﬁcantly lower levels of blood mDC1shigh (p = 0 048)
and pDCshigh (p = 0 017) and expression of HLA-DR
(p = 0 001, p = 0 023, resp.), when compared with the blood
levels of HFDs. Women whose tumours showed a GPR had
no alterations in circulating levels (Table 15).
After 8 cycles of NAC, women whose breast cancers
showed a PPR also had signiﬁcantly lower levels of expres-
sion of mDC1 CD40 (p = 0 001) and CD86 (p = 0 001), com-
pared with HFDs. These ﬁndings were not seen in women
whose tumours had GPRs (Table 16).
Comparison of blood levels of mDC1 expression of
costimulatory and LNH molecules between GPRs and PPRs
showed a signiﬁcant reduction in CD40, CD86, and CD197
expression on circulating mDC1s (p = 0 005, p = 0 004, and
Table 10: Clinical and pathological parameters of patients (n = 33) studied and the Association of pre-NAC tumour-inﬁltrating CD163+
macrophages (TIMs) and pathological complete response (PCR).
Groups
TIMs PCR
Low inﬁltration
(n)
High inﬁltration
(n)
Pearson chi-square
value
p value
Non-PCR
(n)
PCR
(n)
Pearson chi-square
value
p value
Age (years)
<50 6 8
0.002 0.966
8 6
0.308 0.579
≥50 8 11 9 10
BMI (kg/m2)
≤30 10 10
1.193 0.275
11 9
0.247 0.619>30 4 9 6 7
Menopausal
status
Pre 5 11
1.588 0.208
8 8
0.029 0.866
Post 9 8 9 8
Tumour size
<40mm 8 10
0.066 0.797
9 9
0.036 0.849
≥40mm 6 9 8 7
Nodal status
Negative 5 5
0.337 0.561
5 5
0.013 0.909
Positive 9 14 12 11
Tumour grade
1 (low) 1 1
11.270 0.004∗
2 0
9.303 0.010∗2 (moderate) 10 3 10 3
3 (high) 3 15 5 13
Oestrogen
receptor
Negative 2 9
3.970 0.046∗
3 8
3.882 0.049∗
Positive 12 10 14 8
HER-2 receptor
Negative 10 13
0.035 0.853
13 10
0.762 0.383
Positive 4 6 4 6
NAC regimen
AC-TX 6 10
0.308 0.579
6 10
2.443 0.118
AC-T 8 9 11 6
Recurrent
disease(4)
No 8 14
0.992 0.319
7 15
10.252 0.001∗
Yes 6 5 10 1
Death(4)
No 11 16
0.172 0.678
12 15
2.972 0.085
Yes 3 3 5 1
NAC: neoadjuvant chemotherapy; BMI: body mass index (≤30: nonobese, >30: obese); AC-TX: doxorubicin, cyclophosphamide, taxotere, and xeloda®
(capecitabine), respectively; (4)4-year follow-up; ∗statistically signiﬁcant.
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p = 0 003, resp.) following NAC in patients whose tumours
had a PPR (Table 16).
These ﬁndings demonstrate the signiﬁcant association
between the reduced % (mDC1s and pDCs) and expression
of HLA-DR (mDC1s and pDCs), CD40, and CD86 (mDC1s)
and failure to achieve a GPR with NAC. Thus, women whose
breast cancers failed to undergo a GPR with NAC showed
signiﬁcantly reduced, inactive, and immature DC subsets in
the circulation.
4. Discussion
In the current study reported, the CD163+ TIMs (M2 macro-
phage phenotype) in both the primary breast cancer and
metastatic ALNs were signiﬁcantly associated with pCRs in
malignant tissue following NAC. TIMs are derived from cir-
culating monocytes and primitive bone marrow progenitors
[58]. They are recruited into the tumour milieu by various
chemokines (e.g., CCL2) and factors released by necrotic
cells, in response to hypoxia and the cancer-associated
ﬁbroblasts [59]. Once embedded in the tumour microenvi-
ronment, the monocytes mature into the predominant M2
expressing CD163 (haemoglobin scavenger receptor) macro-
phages and are activated by Th 2 cytokines interleukin-4
(IL-4) and IL-10 [19, 60, 61]. The M2 phenotype favours
tumour growth and metastatic spread through the promo-
tion of angiogenesis, production of metalloproteinases, and
inhibition of cytotoxic T lymphocytes (CTLs) by TGF-β
and IL-10. TIMs also secrete arginase 1 in the tumour
microenvironment, reducing L-arginine in situ and inhibit-
ing CTL production and function [19, 60, 62–64]. Bingle
et al., in a meta-analysis of various solid cancers, including
breast cancer, showed that high levels of M2 TIMs were
associated with a poor DFS and OS and this is supported
by other, more recent publications [22, 65].
A pCR following NAC in breast cancer has been shown
in some studies to be a surrogate marker for a good prognosis
and survival [46, 66]. Cortazar et al. described a correlation
between favourable outcome and pCR in breast cancer [67].
Our ﬁndings suggest that high levels of CD163+ TIMs in
LLABCs are a predictor for a good pathological response
and pCR but not necessarily for DFS and OS. In our study,
there was a signiﬁcant association between TIMs and tumour
ER status and grade and between pCR and tumour ER status
and grade. Highly proliferative, triple-negative breast cancers
are signiﬁcantly associated with high rates of pCR but have a
poor DFS and OS [9, 46, 68]. Esserman et al. showed by
studying breast cancer subsets that a pCR was a better predic-
tor for a DFS [69]. A recent analysis revealed that although
patients in whom there was a pCR in the tumour had a more
favourable outcome, this did not always result in an improve-
ment in OS [70].
M1 TIMs are activated by interferon-γ (IFN-γ) and bac-
terial products, produce proinﬂammatory cytokines, express
IL-12, enhance adaptive immunity, and induce lysis of
tumour cells [19–21]. In contrast to the presence of the M2
CD163+ TIMs, the M1CD68+ TIMs had no demonstrable
association with a pCR. Heys et al. studied TIM subsets in
breast cancer, using CD68 (general macrophage marker)
expression of suppression of cytokine signalling (SOCS) 1
and SOCS 3 [24]. SOCS 1 (M2 phenotype) inhibits the proin-
ﬂammatory signalling pathways downstream of IFN-γ and
Toll-like receptor 4, whilst SOCS 3 (M1 phenotype) inhibits
signal transduction and activation of transcription 3 (STAT
3) signalling. High levels of SOCS 3+ TIMs in LLABCs were
associated with a pCR with NAC. There was, however, no
association between SOCS 1+ TIMs and pathological
response to NAC [24]. Thus, M1 and M2 TIM subsets,
characterised by the expression of speciﬁc cellular functional
markers, were associated with signiﬁcant rates of pCR
following NAC.
In sentinel lymph nodes (SLNs), Mansﬁeld et al. found
that the presence of sinusoidal CD163+ M2 macrophages
was associated with a favourable nodal status in patients with
breast cancer. They did not investigate TIMs in metastatic
SLNs [54]. In our study, there was a signiﬁcant association
between the level of CD163+ TIMs in metastases in
tumour-draining ALNs, prior to NAC and the subsequent
pCR following 8 cycles of NAC. Our study, on the other
hand, found no signiﬁcant diﬀerence in the level of CD163+
macrophages in metastatic (tumour-free areas) versus non-
metastatic medullary areas in ALNs. The signiﬁcant associa-
tion between CD163+ TIMs in primary breast cancers and
metastatic ALNs and pCRs with NAC has not been previ-
ously reported.
In patients with cancer, blood neutrophils tend to be
immature and produce low levels of free radicals [26].
Increased levels of blood neutrophils have been documented
in various tumours, including breast cancer, and shown to be
associated with poor clinical outcomes [26]. Their associa-
tion with pathological responses with NAC, however, has
not been described. We did not demonstrate any association
between blood neutrophils and poor clinical outcome, nor
with a pCR in the primary tumour, in our cohort of 108
patients. We did, however, document a signiﬁcant associa-
tion between circulating levels of neutrophils, prior to
NAC, and subsequent pCR in metastatic ALNs, a ﬁnding
not previously described.
There were signiﬁcantly reduced blood levels of PMN
neutrophils following NAC, albeit all patients were given gran-
ulocyte colony-stimulating factor following randomisation.
Tumour entry of PMN neutrophils is induced by chemo-
tactic molecules secreted by intratumoural TIMs and cancer
cells [27, 28]. High levels of CD66b+ TINs have been found
previously to be signiﬁcantly associated with poor DFS and
OS in a variety of nonbreast solid cancers [30–32]. In our
study of women with LLABCs, CD66b+ TINs were not signif-
icantly associated with pathological responses to NAC. They
were also resistant to NAC. The TINs were present in small
numbers in the tumour microenvironment, and only a small
cohort (n = 16) of patients was studied. A larger series is
required to conﬁrm these ﬁndings. There are, however, no
published articles documenting their relevance in women
with LLABCs undergoing NAC.
In tumour-draining metastatic ALNs, there was also no
signiﬁcant association between the level of inﬁltration by
CD66b+ TINs and pCR with NAC. Moreover, there was no
diﬀerence in the level of inﬁltration by CD66b+ neutrophils
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in the paracortical areas of metastatic (tumour-free areas)
and nonmetastatic ALNs. Such ﬁndings have not previously
been documented.
In our study, we investigated tumour-inﬁltrating CD1a+
DCs and concurrently circulating DCs, mDC1shigh and
pDCshigh. In solid cancers, evidence suggests that DCs in
the tumour-microenvironment are present in small numbers,
are immature, and poorly activated [41, 71, 72]. In patients
with operable breast cancer, DCs in both ALNs and in the
circulation have been shown to be dysfunctional [43]. In
breast and ovarian cancer, moreover, TIDCs have been
shown to be immunosuppressive, inhibiting the production
of CTLs [38].
Although the presence of TIDCs has been documented to
be associated with a better clinical outcome in a number of
human solid cancers, this is not the case with CD1a+ TIDCs
in breast cancer [44, 73–75]. There has, however, been no
previously published study regarding CD1a+ TIDCs in
LLABCs and the pathological responses with NAC. Our ﬁnd-
ings showed no signiﬁcant association between the levels of
CD1a+ TIDCs and pCR in either the primary tumours or
metastatic ALNS. There is evidence that DCs in breast cancer
(primary tumours and ALNs) are not only poorly activated
and immature but may be also immunosuppressive, inhibit-
ing the generation of CTLs and inducing T cell tolerance
[38, 41, 43]. Tumour-induced inhibition of DC maturation
and function is an important mechanism exploited by malig-
nant cells to evade anticancer immunity [1, 76, 77]. Dumitriu
et al. showed that DCs in the presence of lung carcinoma cells
in vitro induced the secretion of TGF-β and enhanced the
generation of CD4+CD25+ FOXP3+ Tregs [77]. We found
that NAC signiﬁcantly reduced the levels of intratumoural
CD1a+ DCs although it had no eﬀect on TIMs and TINs.
NAC, by signiﬁcantly reducing suppressor cells (Tregs and
myeloid-derived suppressor cells) within the tumour micro-
environment, may have contributed to the immune-
associated tumour cell death [13, 57]. NAC, concurrently,
had signiﬁcant inhibitory eﬀects on the circulating levels of
DCs in the same cohort of patients.
The percentages of circulating levels of DCs, mDC1s and
pDCs, were signiﬁcantly reduced in women with LLABCs
when compared with healthy females. In addition, the
Table 11: Analyses of blood PMN neutrophils in women with LLABC and speciﬁc clinical and pathological parameters.
Groups
Pre-NAC
median
(range)(3)
p value(4)
(GPR versus PRR, PCR
versus non-PCR)
Post-NAC
median (range)(3)
p value(4) (GPR versus PRR,
PCR versus non-PCR)
Blood
PMNs
Good pathological response
(GPR, n = 52) 4.13 (2.15–11.30)
0.796
3.05 (1.40–6.75)
0.134
Poor pathological
response (PPR, n = 56) 4.07 (1.80–10.10) 3.47 (0.03–8.73)
Pathological complete
response (PCR, n = 29) 4.50 (2.15–11.30)
0.381
3.10 (1.40–6.75)
0.755Nonpathological
complete response
(non-PCR, n = 79)
3.94 (1.80–10.10) 3.26 (0.03–8.73)
Nodal metastasis
(n = 56) 3.94 (1.80–10.10)
0.634
3.11 (0.03–8.26)
0.337
No nodal metastasis
(n = 52) 4.16 (2.15–11.30) 3.36 (1.54–8.73)
Nodal pCR
(n = 16) 5.43 (2.84–10.10)
0.002∗
3.20 (1.40–8.26)
0.892
No nodal pCR
(n = 40) 3.65 (1.80–9.17) 3.05 (0.03–6.37)
Recurrent disease(5)
(n = 23) 4.02 (1.80–8.70)
0.612
3.19 (0.03–5.80)
0.878
No recurrent disease
(n = 85) 4.10 (2.15–11.30) 3.23 (1.33–8.73)
Death(5) (n = 17) 3.87 (2.23–6.64)
0.276
3.00 (0.03–5.42)
0.360
Survive (n = 91) 4.11 (1.80–11.30) 3.23 (1.33–8.73)
LLABC: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)×109 cells/litre; (4)Mann–Whitney U test; (5)4-year follow-up;
∗statistically signiﬁcant.
Table 12: Alteration of blood PMN neutrophils in women with LLABCs undergoing NAC.
Group Pre-NAC median (range)(3) Post-NAC median (range)(3) p value(4) (pre- versus post-NAC)
Blood PMNs (n = 108) 4.09 (1.80–11.30) 3.20 (0.03–8.73) <0.001∗
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; (3)×109 cells/litre; (4)Wilcoxon signed-rank test; ∗statistically signiﬁcant.
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expression of HLA-DR, CD40, and CD83 molecules on the
surface of mDC1s were also signiﬁcantly reduced, as was
HLA-DR expression of pDCs. The expression of the costim-
ulatory molecules CD80/86 was unchanged compared with
healthy females. We did not carry out any functional assays
to ascertain speciﬁc eﬀector functions such as eﬃcacy in anti-
gen presentation and secretion of cytokines. NAC, in partic-
ular anthracyclines and taxanes, is known to disrupt tumour
cells, exposing expression of calreticulin and release of
tumour-associated antigens (TAAs) [78, 79]. This drug com-
bination was used in our NAC study [46].
There was a signiﬁcant diﬀerence in the level of circulat-
ing DCs between those patients whose tumours showed a
good pathological response (GPR; pCR or ≥90% loss of
tumour cell mass) and those whose tumours had a poor path-
ological response (PPR; no or <90% loss of tumour cell mass)
to 8 cycles of NAC. Following NAC, the blood DC levels in
the GPR group were increased and were signiﬁcantly higher
than the levels documented in healthy females. There was
also a signiﬁcantly reduced % of circulating mDC1shigh and
pDCshigh and reduced expression of HLA-DR, CD40, and
CD83 on mDC1shigh and HLA-DR on pDCshigh in those
patients whose tumours showed a PPR to NAC. In addition,
post-NAC patients whose tumours had a GPR had a signiﬁ-
cantly increased expression of HLA-DR, CD40, CD86, and
the LNHR CD197. These signiﬁcant associations suggest a
possible and important interaction between DCs and TAA
presentation to naïve T cells and immune-induced tumour
cell death during NAC. The ﬁndings documented, to the best
of our knowledge, have not been published previously.
Many chemotherapeutic drugs produce short-lived
inhibitory eﬀects on innate and adaptive immune cells. Some
(anthracyclines, taxanes, cyclophosphamide, capecitabine,
and gemcitabine), however, can enhance or suppress speciﬁc
aspects of the immune mechanism and activate immune-
mediated tumour cell death, contributing to the good
pathological responses documented in primary cancers and
metastatic ALNs [13, 79–85], (Kaewkangsadan et al., 2016b
submitted for publication). Chemotherapy, in particular
anthracyclines, induces cancer cell stress and damage with
resultant release of “danger signals” and release of immuno-
genic TAAs, enhancing the production of and tumour inﬁl-
tration by TAA-speciﬁc CD8+ CTLs [78, 86, 87].
Capecitabine is converted to 5-ﬂuorouracil in the body,
increasing the expression of TAAs and inducing antibody-
dependent cell-mediated cytotoxicity [88, 89]. Taxanes have
been shown to increase circulating levels of INF-γ, IL-2,
and IL-6, as well as enhancing NK cell cytotoxicity [80, 90].
Moreover, metronomic low dose cyclophosphamide has
been documented to reduce the number and activity of
FOXP3+ Tregs and to restore T eﬀector and NK cell function
in patients with disseminated disease [81].
Table 13: Percentage of DC subsets and expression of costimulatory and LNH molecules in the circulation of women with LLABCs.
mDC1s and pDCs
% of subsets and costimulatory molecules in women
with LLABCs (n = 30)
% of subsets and costimulatory molecules
in HFDs (n = 10) p value
Lin1−, HLA-DR+ DCs 1.26± 0.20 1.70± 0.30 0.034∗
mDC1high (Lin1−, HLA- DR+,
CD11c+CD1c+)
0.10± 0.04 0.15± 0.05 0.045∗
pDChigh (Lin1−, HLA-DR+,
CD11c+CD303+)
0.03± 0.02 0.06± 0.02 0.041∗
mDC1 HLA-DR+ 47.30± 8.00 65.00± 3.10 0.045∗
pDC HLA-DR+ 48.12± 9.50 65.52± 5.00 0.002∗
mDC1 CD40+ 35.01± 8.00 44.87± 6.50 0.011∗
mDC1 CD80+ 1.40± 0.60 1.87± 0.35 NS
mDC1 CD83+ 3.18± 0.40 4.04± 0.30 0.047∗
mDC1 CD86+ 28.56± 3.00 34.07± 8.00 NS
mDC1 CD197+ 20.35± 4.50 24.68± 9.00 NS
LNH: lymph node homing; LLABCs: large and locally advanced breast cancers; mDC1: myeloid dendritic cell; pDC: plasmacytoid dendritic cell; HFDs: healthy
female donors; NS: nonsigniﬁcant; ∗statistically signiﬁcant.
Table 14: Eﬀect of NAC on blood DC levels in women with
LLABCs.
Pathological responders
DC baseline levels (%)
p value
GPRs + PPRs 1.34± 0.30
GPRs + PPRs versus HFDs NS
GPRs 1.64± 0.25
GPRs versus HFD NS
PPRs 1.29± 0.25
PPRs versus HFDs NS
Pathological responders
DC post-NAC levels (%)
p value
GPRs 3.24± 1.62
GPRs versus HFDs 0.024∗
PPRs 2.17± 0.5
PPRs versus HFDs NS
NAC: neoadjuvant chemotherapy; LLABCs: large and locally advanced
breast cancers; GPRs: good pathological responders (pCR or ≥90%
reduction of invasive disease); PPRs: poor pathological responders (no
response or <90% reduction of invasive disease); HFDs: healthy female
donors; NS: nonsigniﬁcant; ∗statistically signiﬁcant.
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Our study has provided further knowledge and under-
standing of the relevance and contribution of certain compo-
nents of innate immunity to tumour cell death in both the
primary breast cancer and metastases in tumour-draining
ALNs in women with LLABCs undergoing NAC. High levels
of TIMs (M2) appear to induce/enhance pCRs in primary
and ALN metastatic breast cancers probably through their
association with high tumour grade and negative ER status.
High level of expression of VEGF and the resultant increased
vascularity results in enhanced delivery of chemotherapeutic
agents to the tumour cell milieu. Circulating levels of DCs
and expression of HLA-DR and costimulatory molecules
were signiﬁcantly reduced in patients with LLABCs. This
diminished number of activated DCs and thus decreased
capacity to present TAAs (released by NAC and innate NK
cells) to naïve adaptive T cells results in reduced generation
of CTLs. This trend was signiﬁcantly reversed in patients in
whom NAC induced a pCR. These various immune mecha-
nisms highlight the close and important interaction between
innate and adaptive anticancer immunity.
5. Conclusion
There is a signiﬁcant body of evidence documenting the
important contribution by circulating and tumour-
inﬁltrating T eﬀector (CD4+ and CD8+) and regulatory
(FOXP3+ and CTLA-4+) cells and NK cells in immune-
mediated breast cancer cell death in women with LLABCs
Table 15: Percentage of DC subsets and expression of HLA-DR in the blood of women with LLABC undergoing NAC. Baseline (B) levels in
LLABCs versus completion of chemotherapy (CC) levels in diﬀerent responders.
Study group comparisons mDC1
mDC1
pDC
pDC
HLA-DR HLA-DR
Good pathological responders (GPRs: n = 9)
B (%) 0.12± 0.04 36.07± 6.00 0.02± 0.02 50.86± 10.5
CC (%) 0.10± 0.04 46.33± 8.00 0.05± 0.02 58.05± 12.00
B versus CC
(p value)
NS NS NS NS
CC versus HFDs
(p value)
NS NS NS NS
Poor pathological responders (PPRs: n = 7)
B (%) 0.08± 0.03 31.29± 6.00 0.02± 0.02 53.21± 10.00
CC (%) 0.05± 0.03 29.83± 5.00 0.03± 0.02 49.97± 6.00
B versus CC
(p value)
NS NS NS NS
CC versus HFDs
(p value)
0.048∗ 0.001∗ 0.017∗ 0.023∗
Post-NAC GPR versus PPR
GPR CC versus PPR CC
(p value)
NS 0.041∗ NS NS
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; GPRs: complete or ≥90% reduction of tumour cell mass; PPRs: no or
≤90% reduction of tumour cell mass; HFDs: healthy female donors; NS: nonsigniﬁcant; ∗statistically signiﬁcant.
Table 16: Expression (%) of costimulatory and LNH molecules on mDC1s in the blood of women with LLABCs undergoing NAC. Baseline
(B) levels in LLABCs versus completion of chemotherapy (CC) levels in diﬀerent responders.
Study group comparisons CD40 CD80 CD83 CD86 CD197
Good pathological responders (GPR: n = 9)
B (%) 40.60± 10.00 2.02± 1.30 4.45± 0.75 40.97± 14.00 31.29± 8.00
CC (%) 43.13± 10.00 3.83± 2.00 3.71± 1.70 28.66± 7.00 48.34± 14.00
B versus CC
(p value)
NS NS NS NS NS
CC versus HFDs
(p value)
NS NS NS NS NS
Poor pathological responders (PPRs: n = 7)
B (%) 26.80± 10.00 1.48± 0.50 2.98± 2.00 21.37± 10.00 22.73± 6.00
CC (%) 16.80± 8.00 2.29± 1.20 4.47± 1.80 6.81± 6.00 13.83± 5.00
B versus CC
(p value)
NS NS NS NS NS
CC versus HFDs
(p value)
0.001∗ NS NS 0.001∗ NS
Post-NAC GPR versus PPR
GPR CC versus PPR CC
(p value)
0.005∗ NS NS 0.004∗ 0.003∗
LNH: lymph node homing; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; GPRs: complete or >90% reduction of
tumour cell mass; PPRs: no or ≤90% reduction of tumour cell mass; HFDs: healthy female donors; NS: nonsigniﬁcant; ∗statistically signiﬁcant.
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undergoing NAC. Our novel ﬁndings have further increased
our knowledge and documented the important contribution
of innate immunity to tumour cell death in women with
LLABCs undergoing NAC. The signiﬁcant associations
between the beneﬁcial pathological responses (GPR and
pCR) in the tumour microenvironment (primary and ALN
metastases) and key innate immune cells (CD163+ TIMs, cir-
culating PMN neutrophils, and DCs/subsets) complement
our ﬁndings with NK cells and are an important contribution
to theunderstandingofputative anticancer immuneresponses
in NAC, resulting in immune-mediated tumour cell death.
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